Precision biosciences inc stock.

We will never request to mail you a physical check for home office set up or payroll funds. If you are asked for such information, please contact our HR Team by emailing us at [email protected] to verify the legitimacy of the request. Agency recruiters interested in working with us can apply to join our RecruitiFi community.Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.Business Wire. DURHAM, N.C., March 27, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T ...List Alan, the Chief Medical Officer of Precision Biosciences Inc, sale 7,771 shares at $0.79 during a trade that took place back on Apr 27, which means that List Alan is holding 56,496 shares at $6,139 based on the most recent closing price. Stock Fundamentals for DTIL. Current profitability levels for the company are sitting at:Precision BioSciences GAAP EPS of -$0.46 misses by $0.05, revenue of $3.82M misses by $1.29M SA News Mon, Aug. 08, 2022 Precision BioSciences Q2 2022 Earnings Preview

Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3650 +0.0099 (+2.79%) At close: 04:00PM EST. 0.3798 +0.01 (+4.05%) After hours: 06 ...We credit much of our successes not only to our technical know-how, but our commitment to our team and our culture. Precision BioSciences utilizes its proprietary ARCUS Genome Editing method to overcome cancers, cure genetic diseases, and enable development of safer food.

DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ...

Jan 24, 2022 · Even the best stock pickers will make plenty of bad investments. And there's no doubt that Precision BioSciences, Inc. (NASDAQ:DTIL) stock has had a really bad year. In that relatively short period, the share price has plunged 65%. Precision BioSciences may have better days ahead, of course; we've only looked at a one year period. 22 thg 6, 2022 ... Latham & Watkins Represents Precision BioSciences in US$50 Million Offering of Common Stock ... Precision BioSciences, Inc. (Nasdaq: DTIL), a ...DURHAM, N.C., November 28, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, …Get a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more.DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS ...

Get the latest Precision BioSciences Inc (DTIL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …

Get the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions.

Tesla’s stock is predicted to increase in value in 2015, according to Forbes. In January 2015, Forbes noted that Tesla Motors, Inc.On Monday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock jump 2.61% to $0.45. On the same session, the stock had its day’s lowest price of $0.44, but rose to a high of $0.4695. Over the last five days, the stock has gained 30.61%. Precision Biosciences Inc shares have fallen nearly -62.35% since the year began.When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors.Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close …View the latest Precision Biosciences Inc. (DTIL) stock price, news, historical charts, analyst ratings and financial information from WSJ. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …May 9, 2023 · The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.

In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ...Information on stock, financials, earnings, subsidiaries, investors, and executives for Precision BioSciences. Use the PitchBook Platform to explore the full profile. ... Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, A. Biotechnology. Durham, NC. 115 As of 2023 00000 ...WebStock Price Forecast. According to 3 stock analysts, the average 12-month stock price forecast for DTIL stock stock is $3.00, which predicts an increase of ...The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.That heritage lives and thrives today in Elo Life Systems, an independent company focused on food and agriculture. Precision BioSciences completed the spin-out of Elo in December 2021. At the time, gene editing as a clinical intervention to treat – let alone cure – diseases was practically science fiction. But rapid advances and ...WebOn average, Wall Street analysts predict. that Precision Biosciences's share price could reach $2.50 by Sep 19, 2024. The average Precision Biosciences stock price prediction forecasts a potential upside of 472.08% from the current DTIL share price of $0.44.Web

About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …Nov 29, 2023

Business Wire. DURHAM, N.C., March 27, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T ...About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.DURHAM, N.C.--(BUSINESS WIRE)--Nov. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.NSD:DTIL Detailed Stock Analysis, Stock Price Forecast, Analyst Ratings, Financial Analysis, Stock News & Historic QuotesGet the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions.June 23, 2022 at 12:08 PM · 3 min read. Shares of Precision BioSciences, Inc. DTIL have remained up so far this week as the company has entered into an exclusive worldwide in vivo gene-editing ...

Webull offers Precision BioSciences Inc stock information, including NASDAQ: DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to …

SAN DIEGO, Sept. 26, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and six poster presentations at the 28th Annual Congress of the …

About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life ... risks related to ownership of our common stock; ...Overall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure …WebAbout Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …HC Wainwright Adjusts Price Target on Precision BioSciences to $3 From $5, Keeps Buy Rating. Aug. 17. MT. BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT.Complete Precision Biosciences Inc. stock information by Barron's. View real-time DTIL stock price and news, along with industry-best analysis. The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.Feb 24, 2023 · About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Dec 1, 2023 · The short interest in Precision Biosciences Inc (NASDAQ:DTIL) is 0.85 million shares and it means that shorts have 0.83 day (s) to cover. The consensus price target of analysts on Wall Street is $2.63, which implies an increase of 86.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 ... Jun 27, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ... Jun 21, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ... Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding

Overall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation.Dec 1, 2023 · The short interest in Precision Biosciences Inc (NASDAQ:DTIL) is 0.85 million shares and it means that shorts have 0.83 day (s) to cover. The consensus price target of analysts on Wall Street is $2.63, which implies an increase of 86.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 ... Precision BioSciences, Inc. (NASDAQ:DTIL) shareholders should be happy to see the share price up 15% in the last month. But that is meagre solace in the face of the shocking decline over three years.WebThe inducement award consists of an option to purchase (“stock option”) 160,000 shares of Precision’s common stock, par value $0.000005 (the “Common Stock”), which was granted to an ...WebInstagram:https://instagram. delta tripadvisorhow much is a brick of goldbenefits of registering an llc in delawareis service plus home warranty good About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control … oa smith2009 pluribus unum penny DURHAM, N.C.—(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that a late-breaking abstract featuring preclinical data from its PBGENE-DMD program for the potential …Web ai stock short interest Mol Cancer Res. 2019;17 (2):356-369. The molecules and their uses are investigational. Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established. Arcus Biosciences is evaluating novel combinations of investigational medicines in early- and late ...WebPrecision BioSciences Annual Revenue Estimates (Precision BioSciences) The company’s market cap is about $152M, so that would be a roughly 0.3x forward price-to-sales. Considering the industry ...For more information about our programs, see our current corporate deck.Web